Active — Not RecruitingNot Applicable

Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes

China10 participantsStarted 2019-04-28

Plain-language summary

This study evaluates the change of insulin resistance and glucose metabolism of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the treatment of cyclophosphamide.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.
✓. Meet the diagnostic criteria for panniculitis: fat biopsy suggests inflammatory infiltration.
✓. Meet the diagnostic criteria for acquired lipodystrophy syndrome: childhood onset, clinically no nutritional deficiency or catabolism, systemic or partial subcutaneous fat reduction, genetic testing to exclude congenital lipodystrophy syndrome; low leptin level and autoantibodies can aid in diagnosis.

Exclusion criteria

✕. Mature and effective treatment methods are available.
✕. HIV, HBV and HCV were positive.
✕. A the active period of infection.
✕. At the active stage of malignant tumors.
✕. Combination of other fatal diseases.
✕. Existence of mental and psychological diseases.

What they're measuring

Average daily insulin dosage

Timeframe: week 21

Trial details

NCT IDNCT03936829

SponsorChildren's Hospital of Fudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05-31

View on ClinicalTrials.gov More Lipodystrophy Acquired trials